• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Daiichi Sankyo Ltd (OP: DSKYF )

    27.20 -0.40 (-1.45%)
    Streaming Delayed Price Updated: 3:18 PM EST, Jan 24, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Daiichi Sankyo Ltd

    < Previous 1 2 Next >
    FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
    AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data. 
    Via Benzinga
    Exposures Product Safety
    After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
    AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients. 
    Via Benzinga
    Exposures Product Safety
    Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
    AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
    Via Benzinga
    AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
    AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
    Via Benzinga
    Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront
    Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones. 
    Via Talk Markets
    Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
    Via Benzinga
    Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
    Via Benzinga
    Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
    "As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. 
    Via Benzinga
    Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
    Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... 
    Via Benzinga
    Exposures Product Safety
    FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
    The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
    Via Benzinga
    Exposures Product Safety
    5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
    Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
    Via Benzinga
    Why Is AstraZeneca Stock Trading Lower On Tuesday?
    AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. 
    Via Benzinga
    Double Good News For AstraZeneca's Breast Cancer Drugs
    Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
    Via Benzinga
    AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
    FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
    Via Benzinga
    Exposures Product Safety
    What's Going On With Pfizer Stock Today?
    Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. 
    Via Benzinga
    Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
    Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement. 
    Via Benzinga
    Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
    AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
    Via Benzinga
    AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
    Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria 
    Via Benzinga
    FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
    The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in 
    Via Benzinga
    AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
    AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
    Via Benzinga
    AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
    Via Benzinga
    AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
    Via Benzinga
    European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
    Via Benzinga
    With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
    Via Benzinga
    Seagen Suffers Loss In Arbitration Dispute Over ADC Technology
    Via Benzinga
    AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
    Via Benzinga
    Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
    Via Benzinga
    AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
    Via Benzinga
    The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.